Keywords: Cypress Bioscience, Ramius, M&A, BioKineRx

Ramius makes unsolicited, 60% premium offer to buy Cypress Bioscience for $4.00 per share in cash

Article | 20 July 2010

Print This

Shares of USA-based Cypress Biosciences rocketed up almost 40% to $3.41 on news of a takeover offer yesterday from Ramius, which already ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in